Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2009 Financial Results
Date:9/17/2009

cus of the company and aligning our clinical drug programs, we signed a very important partnership for the company in our fourth quarter with Servier, the largest private French Biotech firm, and received immediately $11.0 million with an additional $4.0 million in future research payments and $2.0 million in future product purchases. Together with these payments over the next two years and our most recent rights offering of $28.8 million and the equity raised during this spring of $1.4 million, the new team at Pharmacyclics is responsible for generating more than $45.0 million in new capital." said Robert W. Duggan, Chairman of the Board and Chief Executive Officer. "We now have the funds to progress our four clinical programs in a meaningful way and continue to advance these novel product candidates."

Recent and Upcoming Milestones and Program Updates

  • Raised approximately net $28.0 million in a July 2009 rights offering. This financing gave all existing share holders the opportunity to participate in the company's fund raising. After retiring its loan obligation the rights offering provided net approximately $21.6 million in cash.
  • Partnered PCI-24781, Pharmacyclics' oral HDAC inhibitor, with Servier, granting exclusive licensing for all ex-U.S. markets and providing the company with a royalty on future sales, plus $11.0 million in up front payments, $4.0 million in research payments during the next 24 months as well as potential milestone payments of $24.5 million. PCI -24781 is currently in a U.S. Phase I/II study in patients with Non-Hodgkin's lymphoma and continues to have a class leading safety profile. PCI-24781 was well tolerated in heavily pretreated patients with relapsed/refractory Non-Hodgkin's lymphoma, with promising clinical responses in the Phase I portion of the trial. Data will be presented at the December 2009 ASH meeting in New Orleans. Servier, Pharmacyclics' European partner, is in t
    '/>"/>

SOURCE Pharmacyclics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Pharmacyclics Sets Record Date for Rights Offering
2. Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer
4. Pharmacyclics Receives Nasdaq Notification
5. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
6. Pharmacyclics Reports Third Quarter 2008 Financial Results
7. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
8. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
9. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
10. J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance
11. Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... California (PRWEB) March 05, 2015 Developers ... plugins have announced a new effect preset entitled ... allows users to take advantage of combining halftone and ... competition,” said Christina Austin, CEO of Pixel Film Studios. ... users will love.” , With ProHalftone users can now ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Affirmed Housing ... for Cielo Carmel on March 4 at 10AM. ... speakers: Sherri Lightner, Council president, City of San ... Charmaine Atherton, Senior Vice President, Southern California Community Development, ... & CEO, San Diego Housing Commission. , ...
(Date:3/5/2015)... 2015 In recognition of its ongoing ... Soho Flordis International (SFI) has been honored by the ... global natural medicine company committed to identifying and developing ... safety, and effectiveness. For these efforts the non-profit ABC ... Investment in Phytomedicinal Research Award. , Phytomedicinal research ...
(Date:3/5/2015)... Atlanta, GA (PRWEB) March 05, 2015 ... Kung Fu for Health and Wellness at Atlanta Shaolin ... 2015 on 4350 Peachtree Industrial BLVD, Suite 500A, city ... SCF (Shaolin Chan Foundation), which is a non-profit organization ... culture, arts, philosophy and medicine. , The seminar ...
(Date:3/4/2015)... 2015 Understanding China’s New Medical Device ... – 3:00 p.m. EDT, http://www.fdanews.com/UnderstandingChinaMDRegs , There ... for medical devices in China. , These new ... research and development, approval, manufacturing, distribution, and post-market surveillance. ... in development as well as those that are already ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released ProHalftone Exclusively for Final Cut Pro X Editors 2Health News:SD City Council President Sherri Lightner and Affirmed Housing Break Ground on Affordable Homes in Carmel Valley 2Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 2Health News:SFI Receives Prestigious ABC’s Tyler Award Given For Global Research Effort 3Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 2Health News:Top Martial Arts Master Wu Bin of China, Has Successfully Conducted a Time-Honored Kung Fu Seminar for Health & Wellness at Shaolin Institute, Atlanta, GA 3Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 2Health News:FDAnews Announces: Understanding China’s New Medical Device Regulations Webinar, March 26, 2015 3
... / Heidelberg, 9 January 2012 -- Confronted with a high ... treat aggressively with medications. According to new research, however, delaying ... be harmful. The delay allows doctors and their patients to ... and exercise. According to Neda Laiteerapong and colleagues from the ...
... Center researchers identified a new culprit that leads to ... into plaque and narrows arteries. The research, published online ... explains why cholesterol-laden, coronary artery disease-causing cells called macrophages, ... macrophages that accumulate in plaques secrete a molecule called ...
... Reporter , FRIDAY, Jan. 6 (HealthDay News) -- Annual ... new study that is unlikely to quell the controversy ... "Organized prostate cancer screening when done in addition to ... result in any apparent benefit, but does result in ...
... Jan. 9 (HealthDay News) -- Most parents who have genetic ... children, a new study finds. Researchers interviewed 253 parents ... cancer-related genes (BRCA1 and BRCA2) that can be inherited. All ... time of the genetic test. Twenty-nine percent of the ...
... Researchers at the Translational Genomics Research Institute (TGen) have ... lead to lung cancer in never-smokers a first ... the starting point. We certainly have a lot of ... be very interested in confirming and looking at in ...
... found that when parents get tested for breast cancer genes, ... with those who are very young. Published early online in ... Society, the study also revealed that most parents think that ... test results. For parents, one of the primary motivations ...
Cached Medicine News:Health News:Blood pressure control: Now or later? 2Health News:Researchers discover new culprit in atherosclerosis 2Health News: PSA Test for Prostate Cancer Doesn't Save Lives: Study 2Health News: PSA Test for Prostate Cancer Doesn't Save Lives: Study 3Health News:Most Parents Tell Kids About Test Results for Breast Cancer Genes 2Health News:TGen researchers map potential genetic origins, pathways of lung cancer in nonsmokers 2Health News:Most parents who get tested for breast cancer genes share results with their children 2
(Date:3/4/2015)... Diabetes Care®, Inc. (NASDAQ: TNDM ), a medical ... Pumps, today announced the closing of its previously announced underwritten ... price to the public of $11.50 per share, which includes ... to purchase up to an additional 787,500 shares. All of ... BofA Merrill Lynch and Piper Jaffray ...
(Date:3/4/2015)... March 4, 2015  Nevro Corp. (NYSE: ... and commercialized an innovative, evidence-based neuromodulation platform for the ... release financial results for the fourth quarter  and full ... 18, 2015. Company management will host a conference call ... Time) on Wednesday, March 18, 2015. ...
(Date:3/4/2015)... 4, 2015  Mail-service and specialty pharmacies will ... and government health plans $11.8 billion over the ... Pharmaceutical Care Management Association (PCMA). "Home ... of the easiest ways to reduce health costs," ... . "Policymakers should resist efforts to restrict these ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Closing of Underwritten Public Offering of Common Stock 2PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Illinois Employers, Consumers and Public Programs by $11.8 Billion 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: